2.4. Analysis.
Comparison 2: Casirivimab/imdevimab compared to placebo to prevent COVID‐19 (pre‐exposure prophylaxis), Outcome 4: Adverse events: grade 3 to 4 within 6 months
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.